GTHX Non Current Assets Total from 2010 to 2024
| GTHX Stock | USD 3.72 0.27 6.77% |
Non Current Assets Total | First Reported 2016-12-31 | Previous Quarter 7 M | Current Value 6.6 M | Quarterly Volatility 5.1 M |
Check G1 Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GTHX main balance sheet or income statement drivers, such as Depreciation And Amortization of 291.2 K, Interest Expense of 10.5 M or Selling General Administrative of 46.9 M, as well as many exotic indicators such as Price To Sales Ratio of 1.82, Dividend Yield of 0.0 or PTB Ratio of 3.32. GTHX financial statements analysis is a perfect complement when working with G1 Therapeutics Valuation or Volatility modules.
GTHX | Non Current Assets Total |
Latest G1 Therapeutics' Non Current Assets Total Growth Pattern
Below is the plot of the Non Current Assets Total of G1 Therapeutics over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. G1 Therapeutics' Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in G1 Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Non Current Assets Total | 10 Years Trend |
|
Non Current Assets Total |
| Timeline |
GTHX Non Current Assets Total Regression Statistics
| Arithmetic Mean | 4,007,476 | |
| Geometric Mean | 893,121 | |
| Coefficient Of Variation | 126.69 | |
| Mean Deviation | 4,459,359 | |
| Median | 510,000 | |
| Standard Deviation | 5,077,091 | |
| Sample Variance | 25.8T | |
| Range | 13.7M | |
| R-Value | 0.72 | |
| Mean Square Error | 13.5T | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | 812,454 | |
| Total Sum of Squares | 360.9T |
GTHX Non Current Assets Total History
About G1 Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include G1 Therapeutics income statement, its balance sheet, and the statement of cash flows. G1 Therapeutics investors use historical funamental indicators, such as G1 Therapeutics's Non Current Assets Total, to determine how well the company is positioned to perform in the future. Although G1 Therapeutics investors may use each financial statement separately, they are all related. The changes in G1 Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on G1 Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on G1 Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in G1 Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Assets Total | 6.6 M | 5.9 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards G1 Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, G1 Therapeutics' short interest history, or implied volatility extrapolated from G1 Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of G1 Therapeutics Correlation against competitors. For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.Note that the G1 Therapeutics information on this page should be used as a complementary analysis to other G1 Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for GTHX Stock analysis
When running G1 Therapeutics' price analysis, check to measure G1 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy G1 Therapeutics is operating at the current time. Most of G1 Therapeutics' value examination focuses on studying past and present price action to predict the probability of G1 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move G1 Therapeutics' price. Additionally, you may evaluate how the addition of G1 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is G1 Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of G1 Therapeutics. If investors know GTHX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about G1 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share 1.595 | Quarterly Revenue Growth 0.451 | Return On Assets (0.16) | Return On Equity (0.92) |
The market value of G1 Therapeutics is measured differently than its book value, which is the value of GTHX that is recorded on the company's balance sheet. Investors also form their own opinion of G1 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is G1 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because G1 Therapeutics' market value can be influenced by many factors that don't directly affect G1 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between G1 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if G1 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, G1 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.